![Lu Alleruzzo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Lu Alleruzzo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Direktor/Vorstandsmitglied | 01.01.2009 | - |
Vorstandsvorsitzender | - | - | |
Gründer | 01.01.2009 | - | |
Geschäftsführer | 01.01.2009 | - | |
Präsident | 01.01.2009 | - |
Karriereverlauf von Lu Alleruzzo
Ausbildung von Lu Alleruzzo
University of Missouri | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
- Börse
- Insiders
- Lu Alleruzzo
- Erfahrung